MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
Journal Article

Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma

2023
Request Book From Autostore and Choose the Collection Method
Overview
H3 K27‐altered diffuse midline glioma is a highly lethal pediatric‐type tumor without efficacious treatments. Recent findings have highlighted the heterogeneity among diffuse midline gliomas with different locations and ages. Compared to tumors located in the brain stem and thalamus, the molecular and clinicopathological features of H3 K27‐altered spinal cord glioma are still largely elusive, thus hindering the accurate management of patients. Here we aimed to characterize the clinicopathological and molecular features of H3 K27M‐mutant spinal cord glioma in 77 consecutive cases. We found that the H3 K27M‐mutant spinal cord glioma, with a median age of 35 years old, had a significantly better prognosis than H3 K27M‐mutant brain tumors. We noticed a molecular heterogeneity of H3 K27M‐mutant spinal cord astrocytoma via targeted sequencing with 34 cases. TP53 mutation which occurred in 58.8% of cases is mutually exclusive with PPM1D (26%) and NF1 (44%) mutations. The TP53‐mutant cases had a significantly higher number of copy number variants (CNV) and a marginally higher proportion of pediatric patients (age at diagnosis <18 years old, p = 0.056). Cox regression and Kaplan–Meier curve analysis showed that the higher number of CNV events (≥3), chromosome (Chr) 9p deletion, Chr 10p deletion, ATRX mutation, CDK6 amplification, and retinoblastoma protein (RB) pathway alteration are associated with worse survival. Cox regression analysis with clinicopathological features showed that glioblastoma histological type and a high Ki‐67 index (>10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can also stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway, KRAS/PI3K pathway, and chromosome arms CNV. In conclusion, although all H3 K27M‐mutant spinal cord diffuse glioma were diagnosed as WHO Grade 4, the histological type, molecular features representing chromatin instability, and molecular alterations associated with accelerated cell proliferative activity should not be ignored in clinical management. In a large cohort (n=77), we characterized the molecular, clinicopathological, and prognostic characteristics of H3 K27M‐mutant spinal cord diffuse glioma. ATRX mutation, CDK6 amplification, RB pathway alteration, a higher number of Copy number variant (CNV) events, chromosome (Chr) 9p deletion, and Chr 10p deletion is associated with worse survival. Glioblastoma histological type and a high Ki‐67 index (>10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway and PI3K pathway.